Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.
Source: Andrew Partheniou  (7/13/22)
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments. More >

Three Analysts Like Healthcare Co.'s Upside
Source: Streetwise Reports  (7/11/22)
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care. More >

Pharma Looks To Improve Potential Psychedelic Stroke Drug
Source: Streetwise Reports  (7/11/22)
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. More >

New Drug Is Shown to Help Stopped or Reduced Bile Flow
  (7/10/22)
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report. More >

New DMD Drug Yields 'Compelling' Data
  (7/9/22)
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report. More >

Amended Agreement to Benefit Two Biotech Firms
  (7/8/22)
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report. More >

Co. Makes Financing Deals Around Two of Its Approved Drugs
  (7/7/22)
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report. More >

Strong Data Suggest FDA Will Approve New Lymphoma Drug
  (7/6/22)
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report. More >

The FDA Is Expected to Approve New Narcolepsy Drug
  (7/5/22)
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report. More >

Laser Device Co. Gains FDA Approval for Next-Gen Catheter
Source: Streetwise Reports  (7/5/22)
Ra Medical Systems Inc. shares traded 36% higher after the firm reported it received U.S. FDA 510(k) clearance for its DABRA 2.0 Catheter. The DABRA 2.0 is incorporated into the company's DABRA Excimer Laser System which is used by vascular surgeons in procedures to treat lower extremity and peripheral vascular disease. More >

Trial of New Alzheimer's Drug Slated for Early 2023
  (7/1/22)
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report. More >

MedTech Co.'s Shares Maneuver Higher on Q1 Revenue Growth
Source: Streetwise Reports  (7/1/22)
Shares of personalized, member-focused healthcare solutions company Accolade Inc. traded 29% higher after the company reported financial results for Q1/23 highlighting a 44% YoY increase in revenue and significant improvements in adjusted gross margin. More >

Chen's Top Picks for Q3
Source: Streetwise Reports  (6/30/22)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter. More >

BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Source: Streetwise Reports  (6/30/22)
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses. More >

New Alzheimer's Drug Shows Promise as Monotherapy
  (6/29/22)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report. More >

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains
Source: Streetwise Reports  (6/29/22)
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins. More >

Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment
Source: Streetwise Reports  (6/28/22)
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates. More >

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression
  (6/27/22)
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report. More >

Approval Likely of New Gel for Skin Condition, Analyst Says
  (6/27/22)
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report. More >

EU Biopharma Co. Makes $247M Bid for US Oncology Co.
Source: Streetwise Reports  (6/27/22)
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share. More >

Gene Therapy Co. Releases Data From Huntington's Study
Source: Streetwise Reports  (6/23/22)
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial. More >

PE Firm to Take Health Tech Co. Private in $1.1B Deal
Source: Streetwise Reports  (6/22/22)
Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash. More >

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Source: Streetwise Reports  (6/22/22)
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial. More >

Results of Dermatitis Clinical Trial Due This Summer
  (6/21/22)
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report. More >

New Positive Data Seem to Support Drug Label Expansion
  (6/21/22)
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report. More >